Straight from the Desk
Syz the moment
Live feeds, charts, breaking stories, all day long.
- All
- us
- equities
- Food for Thoughts
- macro
- Bonds
- Central banks
- Asia
- sp500
- technical analysis
- investing
- bitcoin
- markets
- inflation
- interest-rates
- europe
- Crypto
- Commodities
- ETF
- AI
- nvidia
- tech
- Forex
- earnings
- gold
- performance
- Real Estate
- oil
- bank
- geopolitics
- apple
- nasdaq
- Alternatives
- Volatility
- energy
- magnificent-7
- switzerland
- emerging-markets
- sentiment
- tesla
- trading
- ESG
- Money Market
- Middle East
- UK
- assetmanagement
- bankruptcy
- meta
- russia
- Turkey
- France
- amazon
- ethereum
- microsoft
- Industrial-production
- africa
- Healthcare
- Market Outlook
- brics
Annualized Total Returns over the last 7 years...
US Stocks: +8.8% US Bonds: -0.3% US 60/40: +5.4% Source: Charlie Bilello
WeWork has officially filed for bankruptcy
From a $47 billion private market valuation to a $9 billion IPO via a SPAC in 2021, and now trading at $1.32 a share in after hours, marking a jaw-dropping 99% drop from its IPO price. The co-working space drama continues to unfold, reminding us that even unicorns can stumble in the real world of business. Source: Michael Burry Stock Tracker
Beware the short squeeze... CTAs are now short $25 billion of US equities, one of the largest short positions in the 8 years...
Source: Barchart
The US equity market ultra-dominance
Source: Michel A.Arouet, Bloomberg, Goldman Sachs
Elon Musk’s X is worth less than half of price he paid for Twitter
X is worth $19 billion a year after the $44 billion purchase. Employee restricted stock units are awarded at $45 a share. Source: Bloomberg, HolgerZ
As a remainder, Bank of Japan (8301.JP) is a tradeable stock so you can buy some if you wish
Note that the chart does not look pretty... Maybe the market doesn't give much credibility to the management? Source: www.zerohedge.com
Eli Lilly exceptionalism... $LLY vs. rest of Pharma and S&P 500 Healthcare stocks
Source: Goldman Sachs, TME
Investing with intelligence
Our latest research, commentary and market outlooks